<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921230</url>
  </required_header>
  <id_info>
    <org_study_id>S2366</org_study_id>
    <nct_id>NCT02921230</nct_id>
  </id_info>
  <brief_title>Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery</brief_title>
  <acronym>EMINENT</acronym>
  <official_title>A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EMINENT study is a prospective, multi-center study confirming the superior effectiveness
      of the ELUVIA stent versus Self-Expanding Bare Nitinol Stents in the treatment of lesions in
      the femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EMINENT study is a prospective, multi-center study confirming the superior effectiveness
      of the ELUVIA stent versus Self-Expanding Bare Nitinol Stents in the treatment of lesions
      30-140 mm long located in the femoropopliteal arteries in subjects with symptoms classified
      as Rutherford categories 2-4.

      The study is a 2:1 randomized (ELUVIA vs Self-Expanding Bare Nitinol Stents), controlled,
      single-blind, superiority trial (RCT).

      The objective of the study is to confirm the superior effectiveness of the ELUVIA
      Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery
      (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length when compared
      against bare metal stents, and collect additional data including health economics data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency at 12 months post-procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary effectiveness endpoint assesses primary patency at 12 months post-procedure. This effectiveness endpoint is designed to demonstrate that the 12-month primary patency for the ELUVIA treatment group is superior to the Self-Expanding Bare Nitinol Stents treatment group.
Primary vessel patency is defined as a binary endpoint and will be determined to be a success when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit in the absence of clinically-driven TLR or bypass of the target lesion. All DUS readings will be assessed by an independent core laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Walking Improvement</measure>
    <time_frame>12 Months</time_frame>
    <description>Walking Improvement will be assessed and compared between the 2 study arms, by evaluating the change in Six Minute Hall Walk (6MHW) / treadmill test from baseline, or preceding any Target Vessel Revascularization and evaluating change in Walking Impairment Questionnaire (WIQ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>12 Months</time_frame>
    <description>The change in quality of life will be assessed and compared between the 2 study arms, by evaluating change in EuroQol (EQ) - 5 Dimensions (5D) - 5 Levels (5L) questionnaire (EQ-5D-5L™) from baseline, or preceding any Target Vessel Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care costs</measure>
    <time_frame>during index procedure, 1, 6, 12, 24 and 36 months</time_frame>
    <description>To evaluate the health care costs and compare it between the 2 study arms, health care costs associated with index procedure and changes in healthcare utilization over time and associated health care costs will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical improvement will be evaluated by assessing the changes in Rutherford Classification from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic improvement</measure>
    <time_frame>12 months</time_frame>
    <description>The hemodynamic improvement will be evaluated by assessing changes in Ankle-Brachial Index (ABI) from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Walking Improvement</measure>
    <time_frame>1, 6, 24 and 36 months</time_frame>
    <description>Walking Improvement will be assessed and compared between the 2 study arms, by evaluating the change in Six Minute Hall Walk (6MHW) / treadmill test from baseline, or preceding any Target Vessel Revascularization and evaluating change in Walking Impairment Questionnaire (WIQ) from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>1, 9, 24 and 36 months</time_frame>
    <description>Quality of Life Improvement will be assessed at 1 month, 6 months, 9 months, 24 months and 36 months by evaluating the change in EQ-5D-5L™ from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>1, 6, 24 and 36 months</time_frame>
    <description>Clinical improvement will be evaluated by assessing the changes in Rutherford Classification from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemodynamic improvement</measure>
    <time_frame>1, 6, 24 and 36 months</time_frame>
    <description>The hemodynamic improvement will be evaluated by assessing changes in Ankle-Brachial Index (ABI) from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary Patency</measure>
    <time_frame>6, 12, 24 and 36 months</time_frame>
    <description>Primary vessel patency is defined as a binary endpoint and will be determined to be a success when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at follow-up visit in the absence of clinically-driven TLR or bypass of the target lesion. All DUS readings will be assessed by an independent core laboratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event and Major Adverse Event (MAE) rate</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
    <description>Adverse Event rate and Major Adverse Event, defined as all causes of death, target limb major amputation and/or Target Lesion Revascularization, rate at each time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (TLR) Rate</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
    <description>Target Lesion Revascularization is defined as any surgical or percutaneous intervention to the target lesion(s) after the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (TVR) Rate</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
    <description>Target Vessel Revascularization is defined as any surgical or percutaneous intervention to the target vessel after the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical success</measure>
    <time_frame>during index procedure</time_frame>
    <description>Technical success defined as delivery and deployment of the assigned study stent to the target lesion to achieve residual angiographic stenosis no greater than 30% assessed visually</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural success</measure>
    <time_frame>within 24 hours of stenting procedure</time_frame>
    <description>Procedural success defined as technical success with no MAEs noted within 24 hours of the index procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Stent Fractures</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Number of Stent Fractures reported at 12 months and 24 months utilizing the Vascular InterVentional Advances (VIVA) definitions assessed by the x-ray core laboratory</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Atherosclerosis</condition>
  <condition>Vascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>ELUVIA Stent Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control Bare Metal Stent Implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral stenting</intervention_name>
    <description>stent implantation during the index procedure</description>
    <arm_group_label>ELUVIA Stent Implantation</arm_group_label>
    <arm_group_label>control Bare Metal Stent Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects age 18 and older

          2. Subject is willing and able to provide consent before any study-specific test or
             procedure is performed, signs the consent form, and agrees to attend all required
             follow-up visits

          3. Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3 or 4

          4. Stenotic, restenotic or occlusive lesion(s) located in the native Superficial Femoral
             Artery (SFA) and/or Proximal Popliteal Artery (PPA):

               1. Degree of stenosis ≥ 70 % by visual angiographic assessment

               2. Vessel diameter ≥ 4 and ≤ 6 mm

               3. Total lesion length (or series of lesions) ≥ 30 mm and ≤140 mm (Note: Lesion
                  segment(s) must be fully covered with one ELUVIA stent or Self Expanding Bare
                  Nitinol stent)

               4. For occlusive lesions requiring use of re-entry device, lesion length ≤ 120 mm

               5. Target lesion located at least three centimeters above the inferior edge of the
                  femur

          5. Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with
             at least one of three vessels patent (&lt; 50 % stenosis) to the ankle or foot with no
             planned intervention

        Exclusion Criteria:

          1. Previously stented target lesion/vessel

          2. Target lesion/vessel previously treated with drug-coated balloon within 12 months
             prior to randomization/enrollment

          3. Subjects who have undergone prior surgery of the SFA/PPA in the target limb to treat
             atherosclerotic disease

          4. Use of atherectomy, laser or other debulking devices in the target limb SFA/PPA during
             the index procedure

          5. History of major amputation in the target limb

          6. Documented life expectancy less than 24 months due to other medical co-morbid
             condition(s) that could limit the subject's ability to participate in the clinical
             study, limit the subject's compliance with the follow-up requirements, or impact the
             scientific integrity of the clinical study

          7. Known hypersensitivity or contraindication to contrast dye that, in the opinion of the
             investigator, cannot be adequately pre-medicated

          8. Known hypersensitivity/allergy to the stent system or protocol related therapies
             (e.g., nitinol, paclitaxel, or structurally related compounds, polymer or individual
             components, and antiplatelet, anticoagulant, thrombolytic medications)

          9. Platelet count less than 80000 mm3 or more than 600000 mm3 or history of bleeding
             diathesis

         10. Concomitant renal failure with a serum creatinine higher than 2.0 mg/dL

         11. Receiving dialysis or immunosuppressant therapy

         12. History of myocardial infarction (MI) or stroke/cerebrovascular accident (CVA) within
             6 months prior to randomization/enrollment

         13. Unstable angina pectoris at the time of randomization/enrollment

         14. Pregnant, breast feeding, or plan to become pregnant in the next 3 years

         15. Current participation in an investigational drug or device clinical study that has not
             completed the primary endpoint at the time of randomization/ enrollment or that
             clinically interferes with the current study endpoints (Note: studies requiring
             extended follow-up for products that were investigational, but have become
             commercially available since then are not considered investigational studies)

         16. Septicemia at the time of randomization/enrollment

         17. Presence of other hemodynamically significant outflow lesions in the target limb
             requiring intervention at the time of the index procedure

         18. Presence of aneurysm in the target vessel

         19. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to
             randomization/enrollment

         20. Perforated vessel as evidenced by extravasation of contrast media prior to
             randomization/enrollment

         21. Heavily calcified lesions

         22. As applicable by French law, subject who is a protected individual such as an
             incompetent adult or incarcerated person
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sint-Franziskus-Hospital GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yann Goueffic</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes, hôpital Nord Laennec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>An Goethals</last_name>
    <phone>+3232900306</phone>
    <email>an.goethals@genae.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Schutt</last_name>
    <phone>+17634942166</phone>
    <email>angela.schutt@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Jaschke, MD</last_name>
      <email>werner.jaschke@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Werner Jaschke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Kausegger, MD</last_name>
      <email>Klaus.Hausegger@kabeg.at</email>
    </contact>
    <investigator>
      <last_name>Klaus Kausegger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gschwandtner, MD</last_name>
      <email>michael.gschwandtner@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael Gschwandtner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lieven Maene, MD</last_name>
      <email>lmaene@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Lieven Maene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZiekenhuisNetwerk Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Goverde, MD</last_name>
      <email>peter.goverde@zna.be</email>
    </contact>
    <investigator>
      <last_name>Peter Goverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Verbist, MD</last_name>
      <email>jurgen.verbist@imelda.be</email>
    </contact>
    <investigator>
      <last_name>Jurgen Verbist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Deloose, MD</last_name>
      <email>koen.deloose@telenet.be</email>
    </contact>
    <investigator>
      <last_name>Koen Deloose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Hendriks, MD</last_name>
      <email>Jeroen.Hendriks@uza.be</email>
    </contact>
    <investigator>
      <last_name>Jeroen Hendriks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Vermassen, MD</last_name>
      <email>frank.vermassen@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Frank Vermassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Fourneau, MD</last_name>
      <email>Inge.Fourneau@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Inge Fourneau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Keirse, MD</last_name>
      <email>koen.keirse@rztienen.be</email>
    </contact>
    <investigator>
      <last_name>Koen Keirse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Privé Paul D'Egine</name>
      <address>
        <city>Champigny-sur-Marne</city>
        <zip>94500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Becquemin, MD</last_name>
      <email>jpbecquemin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Becquemin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Rosset, MD</last_name>
      <email>erosset@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Eugenio Rosset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L'Hôpital Henri-Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Desgranges, MD</last_name>
      <email>pascal.desgranges@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Desgranges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>77908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Steinmetz, MD</last_name>
      <email>eric.steinmetz@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Steinmetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobocinski, MD</last_name>
      <email>jonathan.sobocinski@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Jonathan Sobocinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Feugier, MD</last_name>
      <email>patrickfeugier@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Feugier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Bartoli, MD</last_name>
      <email>MichelAlain.BARTOLI@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Bartoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicla Settembre, MD</last_name>
      <email>n.settembre@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Nicla Settembre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann Goueffic, MD</last_name>
      <email>yann.goueffic@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Goueffic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>(Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantino Delguidice, MD</last_name>
      <email>constantino.delgiudice@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Constantino Delguidice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loic Guillemot, MD</last_name>
      <email>l.guillemot@ch-saintnazaire.fr</email>
    </contact>
    <investigator>
      <last_name>Loic Guillemot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Thaveau, MD</last_name>
      <email>fabien.thaveau@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien Thaveau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Sauguet, MD</last_name>
      <email>a.sauguet@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Antoine Sauguet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélia Bianchini, MD</last_name>
      <email>bianchini-a@ch-valenciennes.fr</email>
    </contact>
    <investigator>
      <last_name>Aurélia Bianchini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts Herzzentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, MD</last_name>
      <email>Thomas.Zeller@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sankt Gertrauden-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Langhoff, MD</last_name>
      <email>ralf.langhoff@sankt-gertrauden.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Langhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Werner, MD</last_name>
      <email>nikos.werner@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Rammos, MD</last_name>
      <email>Christos.Rammos@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Christos Rammos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhäuser Landkreis Freudenstadt GmbH</name>
      <address>
        <city>Freudenstadt</city>
        <zip>72250</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bea, MD</last_name>
      <email>florian.bea@klf-net.de</email>
    </contact>
    <investigator>
      <last_name>Florian Bea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kath. Marienkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Habermann, MD</last_name>
      <email>habermann.radiologie@marienkrankenhaus.org</email>
    </contact>
    <investigator>
      <last_name>Christian Habermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Erbel, MD</last_name>
      <email>Christian.erbel@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Christian Erbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad-Langensteinbach</name>
      <address>
        <city>Karlsbad</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Blessing, MD</last_name>
      <email>erwin.blessing@kkl.srh.de</email>
    </contact>
    <investigator>
      <last_name>Erwin Blessing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jost Ph Schäfer, MD</last_name>
      <email>jp.schaefer@rad.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Jost Schäfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Johannes Gutenberg-Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Espinola-Klein, MD</last_name>
      <email>espinola@uni-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Christine Espinola-Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Mahnken, MD</last_name>
      <email>andreas.mahnken@staff.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Mahnken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital Muenster</name>
      <address>
        <city>Munster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Torsello, MD</last_name>
      <email>Giovanni.Torsello@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Giovanni Torsello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Diakoniewerk München-Maxvorstadt</name>
      <address>
        <city>München</city>
        <zip>80799</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter von Bilderling, MD</last_name>
      <email>bi@angiopraxis.de</email>
    </contact>
    <investigator>
      <last_name>Peter von Bilderling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Stavroulakis, MD</last_name>
      <email>konstantinos.stavroulakis@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Stavroulakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <zip>49079</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Sunderdiek, MD</last_name>
      <email>ulrich.sunderdiek@mho.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Sunderdiek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Zorger, MD</last_name>
      <email>niels.zorger@barmherzige-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Niels Zorger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Tepe, MD</last_name>
      <email>gunnar.tepe@ro-med.de</email>
    </contact>
    <investigator>
      <last_name>Gunnar Tepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MEDINOS Kliniken Sonneberg GmbH</name>
      <address>
        <city>Sonneberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Thieme, MD</last_name>
      <email>Marcus.Thieme@medinos-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Thieme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landeshauptstadt Stuttgart, Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Götz Martin Richter, MD</last_name>
      <email>G.Richter@klinikum-stuttgart.de</email>
    </contact>
    <investigator>
      <last_name>Götz Martin Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Torgau</name>
      <address>
        <city>Torgau</city>
        <zip>04860</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Maiwald, MD</last_name>
      <email>maiwald@kkh-torgau.de</email>
    </contact>
    <investigator>
      <last_name>Lars Maiwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tübingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Ketelsen, MD</last_name>
      <email>dominik.ketelsen@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Dominik Ketelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nordoberpfalz AG, Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Paetzel, MD</last_name>
      <email>christian.paetzel@kliniken-nordoberpfalz.ag</email>
    </contact>
    <investigator>
      <last_name>Christian Paetzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lee, MD</last_name>
      <email>mlee@rcsi.ie</email>
    </contact>
    <investigator>
      <last_name>Michael Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Chiesa, MD</last_name>
      <email>chiesa.roberto@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Chiesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Montorsi, MD</last_name>
      <email>piero.montorsi@cardiologicomonzino.it</email>
    </contact>
    <investigator>
      <last_name>Piero Montorsi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedaliero Universitaria Federico II</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Esposito, MD</last_name>
      <email>espogiov@unina.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Esposito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Noord West Ziekenhuis Lokatie Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.W. Wallis, MD</last_name>
      <email>j.w.wallis@nwz.nl</email>
    </contact>
    <investigator>
      <last_name>J.W. Wallis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hagaziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <zip>2545</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans van Overhagen, MD</last_name>
      <email>h.voverhagen@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Hans van Overhagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth Tilburg Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Lohle, MD</last_name>
      <email>paullohle@hetnet.nl</email>
    </contact>
    <investigator>
      <last_name>Paul Lohle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Salmeron, MD</last_name>
      <email>rjruizsalmeron@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Rafael Salmeron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Schindewolf, MD</last_name>
      <email>marc.schindewolf@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Marc Schindewolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josua van den Berg, MD</last_name>
      <email>josua.vandenberg@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Josua van den Berg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Bieri, MD</last_name>
      <email>thomas.bieri@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Bieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Pfammatter, MD</last_name>
      <email>Thomas.Pfammatter@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Pfammatter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Bent, MD</last_name>
      <email>clare.bent@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Clare Bent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miltiadis Krokidis, MD</last_name>
      <email>Miltiadis.krokidis@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Miltiadis Krokidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usman Shaikh, MD</last_name>
      <email>Usman.Shaikh@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Usman Shaikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ounali Jaffer, MD</last_name>
      <email>Ounali.Jaffer@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ounali Jaffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Diamantopoulos, MD</last_name>
      <email>Athanasios.Diamantopoulos@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Athanasios Diamantopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Hamady, MD</last_name>
      <email>m.hamady@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mohammed Hamady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirmal Kakani, MD</last_name>
      <email>Nirmal.Kakani@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nirmal Kakani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Nice, MD</last_name>
      <email>Colin.Nice@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Colin Nice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregg Ramjas, MD</last_name>
      <email>Miltiadis.krokidis@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Gregg Ramjas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>Superficial Femoral Artery (SFA)</keyword>
  <keyword>Proximal Popliteal Artery (PPA)</keyword>
  <keyword>stenting</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

